Publication

Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza - Illustration for the Netherlands

Postma, M. J., Novak, A., Scheijbeler, H. W. K. F. H., Gyldmark, M., van Genugten, M. L. L. & Wilschut, J. C., 2007, In : Pharmacoeconomics. 25, 6, p. 497-509 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

Background: Oseltamivir is effective in the treatment of influenza. Utilisation in The Netherlands is limited, but increasing.

Objective: To estimate the cost effectiveness of oseltamivir treatment (vs symptom relief only) for patients with influenza-like illness (ILI) who are at increased risk for serious complications of influenza.

Methods: A cost-effectiveness analysis was used, building on a previously developed model (decision tree) that was applied for evaluating influenza vaccination and pandemic preparedness plans. Three patient subgroups were assessed (elderly patients [aged >= 65 years] without chronic disease, elderly patients with chronic disease, and chronically ill, non-elderly patients). Inputs for the model were taken from various sources including a meta-analysis. A societal perspective was adopted and costs were expressed in E per life-year gained (year 2003 values). Life-years lost were discounted at 4% in accordance with Dutch guidelines. Deterministic and probabilistic sensitivity analyses were employed to assess the robustness of the results.

Results: For chronically ill patients with ILI, visits to the GP for oseltamivir treatment were cost saving. For non-chronically ill elderly patients, incremental cost-effectiveness was estimated at E1759 per life-year gained. Cost savings and favourable cost effectiveness were robust in a deterministic and stochastic sensitivity analysis.

Conclusion: Our model-based analysis suggests that at-risk people presenting with ILI to a GP could be offered oseltamivir at favourable cost effectiveness or even cost savings in the Dutch setting compared with symptom relief with analgesics only.

Original languageEnglish
Pages (from-to)497-509
Number of pages13
JournalPharmacoeconomics
Volume25
Issue number6
Publication statusPublished - 2007

    Keywords

  • NEURAMINIDASE INHIBITOR OSELTAMIVIR, RANDOMIZED CONTROLLED-TRIAL, HEALTHY WORKING ADULTS, B VIRUS-INFECTIONS, PANDEMIC INFLUENZA, ANTIVIRAL THERAPY, VACCINATION, PREVENTION, EFFICACY, IMPACT

Download statistics

No data available

ID: 4581901